AstraZeneca, GSK and Johnson & Johnson have joined forces with the tech transfer offices of three universities to form the Apollo Therapeutics Fund.
Pharmaceutical firms AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson set up a £40m ($57m) commercialisation fund yesterday with the support of Imperial College London, University College London (UCL) and Cambridge University.
Johnson & Johnson joined the consortium through corporate venturing subsidiary Johnson & Johnson Innovation. The three universities are participating through their respective tech transfer offices (TTOs): Imperial Innovations, UCL Business and Cambridge Enterprise.
Each of the corporates has committed to invest £10m over the next six years, while the…
